Forty-nine out of 54 patients with histologically proven diagnosis of NSCLC (adenocarcinoma or other non-small cell histology) and with an EGFR gene mutation treated in our center between June 2010 and July 2014 were considered eligible. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.